Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

RIPK2 activates CYLD. 2 / 2

| 2

➶

reach

"In turn, RIPK2 inhibition by siRNA prevented activation of NF-kappaB and ERK1/2 and completely abolished the protective effect of CYLD deficiency with respect to the production of IL-6, NO, ROS, and pathogen control."

26834734

➶

reach

"To study whether increased RIPK2 levels in Cyld -/- BMDM led to the increased activation of NF-kappaB and MAPKs pathways, IFN-gamma-stimulated WT and Cyld -/- BMDM were treated with RIPK2 and control siRNA, respectively, for 48h prior to Lm infection."

26834734

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...